Sonoma Pharmaceuticals, Inc.SNOA
Price (close)
$1.25
Market cap
$6.0M
P/E
—
Revenue (TTM)
$21.9M
Net income
-$2.3M
Dividend yield
—
1-year total return
-69.3%
Net margin
-10.3%
Revenue growth
47.0%
Debt / equity
0.02x
What Sonoma Pharmaceuticals, Inc. does.
Inc. in 1999 under the laws of the State of California. We changed our name to Oculus Innovative Sciences, Inc. in 2001. In December 2006
we reincorporated under the laws of the State of Delaware, and in December 2016 we changed our name to Sonoma Pharmaceuticals, Inc.
Conestoga Court, Suite 150, Boulder, Colorado 80301. We have two active wholly-owned subsidiaries: Oculus Technologies of Mexico, S.A.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $18.6M | $12.6M | $13.3M | $12.7M | $14.3M | $19.5M |
| Net income | -$4.0M | -$5.1M | -$5.2M | -$4.8M | -$3.5M | -$3.2M |
| Free cash flow | -$3.6M | -$4.4M | -$6.4M | -$2.4M | -$168,000 | -$4.1M |
More on SNOA.
- Sonoma Pharmaceuticals, Inc. summary
- Sonoma Pharmaceuticals, Inc. financial statements
- Sonoma Pharmaceuticals, Inc. key metrics
- Sonoma Pharmaceuticals, Inc. health scores and style box
- Sonoma Pharmaceuticals, Inc. earnings
- Sonoma Pharmaceuticals, Inc. dividends
- Sonoma Pharmaceuticals, Inc. valuation
- Sonoma Pharmaceuticals, Inc. ownership and insiders
- Sonoma Pharmaceuticals, Inc. peers
Figures from Sonoma Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.